On Tuesday, Adma Biologics Inc (NASDAQ: ADMA) was 1.63% up from the session before settling in for the closing price of $21.47. A 52-week range for ADMA has been $3.60 – $23.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 73.26%. When this article was written, the company’s average yearly earnings per share was at 494.23%. With a float of $228.41 million, this company’s outstanding shares have now reached $236.39 million.
Let’s determine the extent of company efficiency that accounts for 624 employees. In terms of profitability, gross margin is 48.79%, operating margin of 30.01%, and the pretax margin is 19.16%.
Adma Biologics Inc (ADMA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adma Biologics Inc stocks. The insider ownership of Adma Biologics Inc is 3.38%, while institutional ownership is 88.31%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 0.04 earnings per share (EPS) during the time that was better than consensus figure (set at 0.01) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 494.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.00% during the next five years compared to 38.68% growth over the previous five years of trading.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
You can see what Adma Biologics Inc (ADMA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.47. Likewise, its price to free cash flow for the trailing twelve months is 64.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.28, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.73 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Looking closely at Adma Biologics Inc (NASDAQ: ADMA), its last 5-days average volume was 2.38 million, which is a drop from its year-to-date volume of 3.63 million. As of the previous 9 days, the stock’s Stochastic %D was 76.95%. Additionally, its Average True Range was 1.04.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 86.45%, which indicates a significant increase from 61.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.60% in the past 14 days, which was lower than the 77.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.98, while its 200-day Moving Average is $12.42. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $22.09. Second resistance stands at $22.37. The third major resistance level sits at $22.87. If the price goes on to break the first support level at $21.31, it is likely to go to the next support level at $20.81. Now, if the price goes above the second support level, the third support stands at $20.53.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are 236,390K outstanding shares of the company, which has a market capitalization of 5.16 billion. As of now, sales total 258,220 K while income totals -28,240 K. Its latest quarter income was 119,840 K while its last quarter net income were 35,910 K.
